This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, W. Y. Articles by Kaelin, W. G. Search for Related Content PubMed PubMed Citation Articles by Kim, W. Y. Articles by Kaelin, W. G.

Role of VHL Gene Mutation in Human Cancer

From the Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Address reprint requests to William G. Kaelin Jr, MD, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; e-mail: william_kaelin{at}dfci.harvard.edu

Germline inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene causes the von Hippel-Lindau hereditary cancer syndrome, and somatic mutations of this gene have been linked to the development of sporadic hemangioblastomas and clear-cell renal carcinomas. The VHL tumor suppressor protein (pVHL), through its oxygen-dependent polyubiquitylation of hypoxia-inducible factor (HIF), plays a central role in the mammalian oxygen-sensing pathway. This interaction between pVHL and HIF is governed by post-translational prolyl hydroxylation of HIF in the presence of oxygen by a conserved family of Egl-nine (EGLN) enzymes. In the absence of pVHL, HIF becomes stabilized and is free to induce the expression of its target genes, many of which are important in regulating angiogenesis, cell growth, or cell survival. Moreover, preliminary data indicate that HIF plays a critical role in pVHL-defective tumor formation, raising the possibility that drugs directed against HIF or its downstream targets (such as vascular endothelial growth factor) might one day play a role in the treatment of hemangioblastoma and renal cell carcinoma. On the other hand, clear genotype-phenotype correlations are emerging in VHL disease and can be rationalized if pVHL has functions separate from its control of HIF.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				S. Negrier Temsirolimus in metastatic renal cell carcinoma Ann. Onc., August 1, 2008; 19(8): 1369 - 1370. [Full Text] [PDF]

				M. L. Nickerson, E. Jaeger, Y. Shi, J. A. Durocher, S. Mahurkar, D. Zaridze, V. Matveev, V. Janout, H. Kollarova, V. Bencko, et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors Clin. Cancer Res., August 1, 2008; 14(15): 4726 - 4734. [Abstract] [Full Text] [PDF]

				I. J. Frew, A. Minola, S. Georgiev, M. Hitz, H. Moch, S. Richard, A. O. Vortmeyer, and W. Krek Combined Vhlh and Pten Mutation Causes Genital Tract Cystadenoma and Squamous Metaplasia Mol. Cell. Biol., July 15, 2008; 28(14): 4536 - 4548. [Abstract] [Full Text] [PDF]

				I. J. Frew and W. Krek pVHL: A Multipurpose Adaptor Protein Sci. Signal., June 17, 2008; 1(24): pe30 - pe30. [Abstract] [Full Text] [PDF]

				M. J. Percy, P. A. Beer, G. Campbell, A. W. Dekker, A. R. Green, D. Oscier, M. G. Rainey, R. van Wijk, M. Wood, T. R. J. Lappin, et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis Blood, June 1, 2008; 111(11): 5400 - 5402. [Abstract] [Full Text] [PDF]

				R. M. Bukowski How I Treat Renal Cell Carcinoma J. Oncol. Pract, May 1, 2008; 4(3): 150 - 152. [Full Text] [PDF]

				T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji, T. Suzuki, A. Kobayashi, J. Yokota, T. Sakiyama, et al. Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth Cancer Res., March 1, 2008; 68(5): 1303 - 1309. [Abstract] [Full Text] [PDF]

				K. M. Smits, L. J. Schouten, B. A.C. van Dijk, C. A. Hulsbergen-van de Kaa, K. A.D. Wouters, E. Oosterwijk, M. van Engeland, and P. A. van den Brandt Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis Clin. Cancer Res., February 1, 2008; 14(3): 782 - 787. [Abstract] [Full Text] [PDF]

				J. Liu and R. Nussinov Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design PNAS, January 22, 2008; 105(3): 901 - 906. [Abstract] [Full Text] [PDF]

				V. A. Carroll and M. Ashcroft Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma Cancer Res., January 15, 2008; 68(2): 545 - 552. [Abstract] [Full Text] [PDF]

				S. Galban, Y. Kuwano, R. Pullmann Jr., J. L. Martindale, H. H. Kim, A. Lal, K. Abdelmohsen, X. Yang, Y. Dang, J. O. Liu, et al. RNA-Binding Proteins HuR and PTB Promote the Translation of Hypoxia-Inducible Factor 1{alpha} Mol. Cell. Biol., January 1, 2008; 28(1): 93 - 107. [Abstract] [Full Text] [PDF]

				C. Bex, K. Knauth, S. Dambacher, and A. Buchberger A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein Nucleic Acids Res., December 18, 2007; 35(21): e142 - e142. [Abstract] [Full Text] [PDF]

				L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]

				K. Guse, T. Ranki, M. Ala-Opas, P. Bono, M. Sarkioja, M. Rajecki, A. Kanerva, T. Hakkarainen, and A. Hemminki Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses Mol. Cancer Ther., October 1, 2007; 6(10): 2728 - 2736. [Abstract] [Full Text] [PDF]

				L. Li, L. Zhang, X. Zhang, Q. Yan, Y. A. Minamishima, A. F. Olumi, M. Mao, S. Bartz, and W. G. Kaelin Jr. Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations Mol. Cell. Biol., August 1, 2007; 27(15): 5381 - 5392. [Abstract] [Full Text] [PDF]

				H. Hirata, Y. Hinoda, N. Kikuno, K. Kawamoto, Y. Suehiro, Y. Tanaka, and R. Dahiya MDM2 SNP309 Polymorphism as Risk Factor for Susceptibility and Poor Prognosis in Renal Cell Carcinoma Clin. Cancer Res., July 15, 2007; 13(14): 4123 - 4129. [Abstract] [Full Text] [PDF]

				S. C. Land and A. R. Tee Hypoxia-inducible Factor 1{alpha} Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif J. Biol. Chem., July 13, 2007; 282(28): 20534 - 20543. [Abstract] [Full Text] [PDF]

				H. Inoue, N. Nonomura, Y. Kojima, M. Shiba, D. Oka, Y. Arai, M. Nakayama, H. Takayama, K. Nishimura, H. Mori, et al. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2052 - 2055. [Abstract] [Full Text] [PDF]

				M. N. Stein and K. T. Flaherty CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma Clin. Cancer Res., July 1, 2007; 13(13): 3765 - 3770. [Full Text] [PDF]

				P. D. Sutphin, D. A. Chan, J. M. Li, S. Turcotte, A. J. Krieg, and A. J. Giaccia Targeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells Cancer Res., June 15, 2007; 67(12): 5896 - 5905. [Abstract] [Full Text] [PDF]

				E. D. MacKenzie, M. A. Selak, D. A. Tennant, L. J. Payne, S. Crosby, C. M. Frederiksen, D. G. Watson, and E. Gottlieb Cell-Permeating {alpha}-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells Mol. Cell. Biol., May 1, 2007; 27(9): 3282 - 3289. [Abstract] [Full Text] [PDF]

				W. G. Kaelin Jr. The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 680s - 684s. [Abstract] [Full Text] [PDF]

				R. Skoda The Genetic Basis of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 1 - 10. [Abstract] [Full Text] [PDF]

				B. Seliger, A. Fedorushchenko, W. Brenner, A. Ackermann, D. Atkins, S. Hanash, and R. Lichtenfels Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1] Clin. Cancer Res., January 1, 2007; 13(1): 27 - 37. [Abstract] [Full Text] [PDF]

				P. H. Patel, R. S.V. Chadalavada, R.S.K. Chaganti, and R. J. Motzer Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma Clin. Cancer Res., December 15, 2006; 12(24): 7215 - 7220. [Abstract] [Full Text] [PDF]

				S. M. Welford, B. Bedogni, K. Gradin, L. Poellinger, M. Broome Powell, and A. J. Giaccia HIF1{alpha} delays premature senescence through the activation of MIF Genes & Dev., December 15, 2006; 20(24): 3366 - 3371. [Abstract] [Full Text] [PDF]

				R. J. Motzer and R. M. Bukowski Targeted Therapy for Metastatic Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5601 - 5608. [Abstract] [Full Text] [PDF]

				G. L. Semenza Baffled by Bafilomycin: An Anticancer Agent That Induces Hypoxia-Inducible Factor-1{alpha} Expression Mol. Pharmacol., December 1, 2006; 70(6): 1841 - 1843. [Abstract] [Full Text] [PDF]

				R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]

				E. Barroso, R.L. Milne, L.P. Fernandez, P. Zamora, J.I. Arias, J. Benitez, and G. Ribas FANCD2 associated with sporadic breast cancer risk Carcinogenesis, September 1, 2006; 27(9): 1930 - 1937. [Abstract] [Full Text] [PDF]

				M. S. Lutz and R. D. Burk Primary cilium formation requires von hippel-lindau gene function in renal-derived cells. Cancer Res., July 15, 2006; 66(14): 6903 - 6907. [Abstract] [Full Text] [PDF]

				S. Patyna, A. D. Laird, D. B. Mendel, A.-M. O'Farrell, C. Liang, H. Guan, T. Vojkovsky, S. Vasile, X. Wang, J. Chen, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol. Cancer Ther., July 1, 2006; 5(7): 1774 - 1782. [Abstract] [Full Text] [PDF]

				B. Pasche A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA, June 7, 2006; 295(21): 2537 - 2538. [Full Text] [PDF]

				J. A. Garcia HIFing the Brakes: Therapeutic Opportunities for Treatment of Human Malignancies Sci. Signal., May 30, 2006; 2006(337): pe25 - pe25. [Abstract] [Full Text] [PDF]

				T. Hsu, Y. Adereth, N. Kose, and V. Dammai Endocytic Function of von Hippel-Lindau Tumor Suppressor Protein Regulates Surface Localization of Fibroblast Growth Factor Receptor 1 and Cell Motility J. Biol. Chem., April 28, 2006; 281(17): 12069 - 12080. [Abstract] [Full Text] [PDF]

				C. V. Dang Oncogenic Activation of Reactive Oxygen Species, Genomic Instability, and Tumorigenesis Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 245 - 248. [Full Text] [PDF]

				X. Kong, Z. Lin, D. Liang, D. Fath, N. Sang, and J. Caro Histone Deacetylase Inhibitors Induce VHL and Ubiquitin-Independent Proteasomal Degradation of Hypoxia-Inducible Factor 1{alpha}. Mol. Cell. Biol., March 1, 2006; 26(6): 2019 - 2028. [Abstract] [Full Text] [PDF]

				B. Krishnamachary, D. Zagzag, H. Nagasawa, K. Rainey, H. Okuyama, J. H. Baek, and G. L. Semenza Hypoxia-Inducible Factor-1-Dependent Repression of E-cadherin in von Hippel-Lindau Tumor Suppressor-Null Renal Cell Carcinoma Mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res., March 1, 2006; 66(5): 2725 - 2731. [Abstract] [Full Text] [PDF]

				R. E. Banks, P. Tirukonda, C. Taylor, N. Hornigold, D. Astuti, D. Cohen, E. R. Maher, A. J. Stanley, P. Harnden, A. Joyce, et al. Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer Cancer Res., February 15, 2006; 66(4): 2000 - 2011. [Abstract] [Full Text] [PDF]

				E. Nakamura, P. Abreu-e-Lima, Y. Awakura, T. Inoue, T. Kamoto, O. Ogawa, H. Kotani, T. Manabe, G.-J. Zhang, K. Kondo, et al. Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor Protein Am. J. Pathol., February 1, 2006; 168(2): 574 - 584. [Abstract] [Full Text] [PDF]

				A. Ciechanover The ubiquitin proteolytic system: From a vague idea, through basic mechanisms, and onto human diseases and drug targeting Neurology, January 24, 2006; 66(1_suppl_1): S7 - S19. [Full Text] [PDF]

				A. Kobayashi, M.-I. Kang, Y. Watai, K. I. Tong, T. Shibata, K. Uchida, and M. Yamamoto Oxidative and Electrophilic Stresses Activate Nrf2 through Inhibition of Ubiquitination Activity of Keap1 Mol. Cell. Biol., January 1, 2006; 26(1): 221 - 229. [Abstract] [Full Text] [PDF]

				H. T. Cohen and F. J. McGovern Renal-Cell Carcinoma N. Engl. J. Med., December 8, 2005; 353(23): 2477 - 2490. [Full Text] [PDF]